InvestorWire NewsRoom


Articles Category: Biotechnology
Monday Sep 26, 2022 - 9:45 am

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailmentsOdyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to commercial fulfillmentThe therapeutic solution, currently known as PRV-002, is designed to…

Continue Reading

Tuesday Sep 20, 2022 - 12:00 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose

First dose is administered as first-ever novel psilocybin analog enters clinical developmentCybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybinThe high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) has reached a milestone in its mission to create safe and effective…

Continue Reading

Tuesday Sep 20, 2022 - 11:15 am

QSAM Biosciences Inc. (QSAM) Working to Halt, Regress Bone Tumors in Children Through Therapeutic Radiopharmaceuticals

Overall incidence of childhood cancer is on the increase, averaging 0.8% increase per year since 1975, reports leading advocacy organizationQSAM developing therapeutic radiopharmaceuticals as safer, more efficacious alternatives to address unmet medical needs, underserved patient populationsCompany creating pipeline of novel radiotherapeutics to serve multiple indications with its lead product, CycloSam With the overall incidence of childhood cancer on the rise, the work of QSAM Biosciences…

Continue Reading

Tuesday Sep 20, 2022 - 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Is ‘One to Watch’

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhereIn September 2022, the company announced it was granted a patent for its 12-lead ECG Patch Monitor, opening a pathway to ischemia and arrhythmia detection innovation in ECG Patch productsIn August 2022, the company announced it was seeking FDA approval for its HeartBeam AIMI…

Continue Reading

Monday Sep 19, 2022 - 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Participates in H.C. Wainwright 24th Annual Global Investment Conference, Presenting Key Investor Highlights on Novel Anthracycline Berubicin for GBM Treatment

Glioblastoma multiforme (“GBM”) is one of the most aggressive, deadly, and treatment-resistant forms of cancer within the brain, with an average life expectancy of 12-18 months and more than 50,000 new cases each yearThe current standard of care for GBM is ineffective for approximately 60% of patientsInitial Phase 1 trial information for Berubicin (approximately 14 years ago) resulted in one patient surviving cancer-free to present…

Continue Reading

Thursday Sep 15, 2022 - 9:00 am

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needsThe company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequencesThrough animal studies, Odyssey has so far evidenced that PRV-002 can easily cross the blood-brain barrier to rapidly eliminate the swelling,…

Continue Reading

Tuesday Sep 13, 2022 - 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Takes Aim at Thus-far Incurable GBM Brain Cancer with Human Drug Trials

U.S.-based drug innovator CNS Pharmaceuticals is enrolling patients in a global clinic trial to evaluate the performance of the company’s lead drug candidate, Berubicin, in fighting glioblastomasGlioblastoma is an incurable brain cancer that is aggressive in its progression and recurrence, leaving most patients with a life expectancy of less than a year after diagnosisCNS’s efforts to fill an unmet medical need arise from promise shown…

Continue Reading

Monday Sep 12, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatmentThe CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spansOdyssey provides a portfolio of diverse technologies and related medical products to meet the unmet medical needs of concussion and TBI patients Each…

Continue Reading

Friday Sep 09, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Efforts to Combat GBM Brain Cancer Proceed Amid Competitive Field

CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumorsGlioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cureCNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, BerubicinBerubicin…

Continue Reading

Wednesday Sep 07, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stageThe approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stageThe pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the…

Continue Reading

Wednesday Sep 07, 2022 - 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Posts Slight Q2 2022 Performance Improvement; Maintains Priorities and Focus on Advancing its Clinical Development Program for Berubicin

CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 millionThe company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million…

Continue Reading

Wednesday Aug 31, 2022 - 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybinThese results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybinAfter receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (, showing promise in treating alcohol addiction…

Continue Reading

Tuesday Aug 30, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking to Fill Glioblastoma Multiforme Treatment Gap with Berubicin Drug Product

CNS Pharmaceuticals is currently undertaking a potentially pivotal global study evaluating the efficacy and safety of Berubicin compared with Lomustine administered after first-line therapy for the treatment of recurrent glioblastoma multiforme (“GBM”)GBM is an aggressive form of cancer that occurs in the brain or spinal cordIn the U.S., it affects between 12,000-15,000 new patients annually with a median survival rate of only 14.6 months from…

Continue Reading

Friday Aug 26, 2022 - 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patternsCYBN is leading the industry in developing proprietary psychedelic-based therapeuticsThe company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin…

Continue Reading

Monday Aug 22, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needsRecently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trialThe MAD arm thus far shows that the drug…

Continue Reading

Wednesday Aug 17, 2022 - 9:30 am

Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF

Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo in June, 2021 to “to determine the effects of psilocybin…

Continue Reading

Thursday Aug 11, 2022 - 9:30 am

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladiesThe company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteersOdyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts…

Continue Reading

Thursday Aug 04, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pitsAnother long-standing concern among service personnel is the treatment of concussive brain injuriesAlthough no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in…

Continue Reading

Wednesday Aug 03, 2022 - 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery systemResults of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time pointKetamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at…

Continue Reading

Tuesday Aug 02, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Seeks to Address Variability of Immune Responses

Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allograftingThe Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on…

Continue Reading

Tuesday Aug 02, 2022 - 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expanding Scope of Potentially Pivotal Study as Part of Clinical Program to Develop GBM Treatment

CNS Pharmaceuticals is undertaking a Berubicin clinical development program targeting glioblastoma multiforme (“GBM”), the most common and devastating primary malignant brain tumorGBM has an incidence rate of 3.21 per 100,000 in the U.S. and up to 5 per 100,000 globally, with studies noting that the latter figure is risingCNS recently received approval for a protocol amendment as part of its potentially pivotal study evaluating the…

Continue Reading

Monday Aug 01, 2022 - 11:15 am

With People in Sports and Military Service Worried About Long-Term Consequences of Traumatic Brain Injuries, Odyssey Health, Inc. (ODYY) Is Working to Offer Relief with PRV-002 Concussion Drug

Players and military service members often retire with debilitating traumatic brain injuries (“TBIs”), including concussions, that lessen the quality of life and present neurological problems as they continue to ageOdyssey has developed PRV-002, a novel compound for treating concussion, and a novel breath-propelled nasal delivery device for delivering the drug deep into the nasal cavityThe PRV-002 drug is expected to offer reprieve to people suffering…

Continue Reading

Thursday Jul 28, 2022 - 10:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants

Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearanceEnrollment for Phase 1/2a trial has already startedUpcoming trial is first time a psilocybin analog will be evaluated for MDD treatmentStudies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin In a first-ever milestone, Cybin (NEO: CYBN) (NYSE American: CYBN) received approval from the…

Continue Reading

Thursday Jul 28, 2022 - 9:00 am

Pro Athletes Provide Specialized Advocacy for Odyssey Health, Inc.’s (ODYY) Solution for Concussion-related Brain Injuries

CDC estimates put the incidence of athlete concussion incidents at 5 to 10 percent of playersCurrently, there is no FDA-approved medicinal treatment for helping people with concussion injuriesOdyssey Health Inc. is a company developing a drug-device combination to treat concussion patients in the first minutes after injuryRetired pro soccer and football athletes Abby Wambach, Kurt Warner, and Brett Favre, have formed a Sports Advisory Board…

Continue Reading

Tuesday Jul 26, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY), Determined to Introduce the Market’s First FDA Approved Concussion Treatment Drug

PBS News Hour estimates that, for college students, concussions cost between $446 million and $1.5 billion annually, while for high school students the cost ranges from $5.4 billion to $19.2 billionOdyssey, through its flagship product, PRV-002, hopes to offer the first FDA-approved drug treatment for concussionsOnce approved, Odyssey is confident that PRV-002 will bring relief to thousands of victims, reduce the cost of concussion treatment…

Continue Reading

Monday Jul 25, 2022 - 11:15 am

Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study

Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage LaboratoriesRecent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug deliverySPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in subcutaneous delivery of novel liposomes vs. intravenous injection Silo Pharma (OTCQB: SILO), a…

Continue Reading

Monday Jul 25, 2022 - 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Completes Acquisition of Largest-Ever DMT Study

Data from newly acquired study could accelerate clinical development of CYBN’s CYB004 by nine monthsThe pivotal study was designed with four primary objectivesCybin’s proprietary substance has potential to effectively treat anxiety disorders, including GAD and SAD Cybin (NEO: CYBN) (NYSE American: CYBN) has completed the acquisition of the largest dimethyltryptamine (“DMT”) study to date, a Phase 1 N,N-DMT study that provides key data relating to the…

Continue Reading

Friday Jul 22, 2022 - 9:00 am

Successful Early Testing of Concussion Therapy Drives Optimism for Odyssey Health, Inc. (ODYY) as Next-stage Trials are Readied

Medical technology innovator Odyssey Health Inc. is using clinical tests to establish the safety of a therapy designed to treat concussion injuries in its earliest moments The company is enthused by results from the early-stage testing and is preparing to design a Phase II/III trial that will target efficacy results in volunteer subjects, focusing particularly on members of the military Odyssey’s technology combines a synthetic medication with…

Continue Reading

Wednesday Jul 20, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Responds to Growing Concerns About Concussion Head Injuries with Drug Device in Clinical Trial

As awareness of the long-term hazards of concussive head injuries for young athletes has increased during the past decade, advocates and business enterprises have stepped up to improve coach responsiveness to players’ conditionWhile efforts primarily focus on assessing injury, Odyssey Health Inc. is developing a product it hopes to become the first drug device with FDA approval for treating a concussed patient after injuryOdyssey is…

Continue Reading

Tuesday Jul 19, 2022 - 9:45 am

QSAM Biosciences Inc. (QSAM) Marks Milestone with Dosing of First Patient in CycloSam Clinical Trial

Treating patients with primary or secondary bone cancer remains goal, says company CEORadiopharmaceuticals is a new class of drugs that delivers radiation therapy directly to cancer cellsQSAM is working to develop CycloSam(R) as a breakthrough therapeutic for adult and pediatric bone cancer patients QSAM Biosciences (OTCQB: QSAM), a company developing a new class of drugs called radiopharmaceuticals, is leading the charge to evaluate a new treatment…

Continue Reading

Wednesday Jul 13, 2022 - 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing…

Continue Reading

Monday Jul 11, 2022 - 12:00 pm

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

Odyssey’s Sports Advisory Board (“SAB”) was formed in 2021 to enhance public awareness of traumatic brain injuries and concussionThe board’s members – Abby Wambach, Kurt Warner, and Brett Favre – have had storied careers in their respective sports and have expressed hope that scientists will examine their brains after their death to advance their understanding of head traumaAbby Wambach has committed her brain to research,…

Continue Reading

Wednesday Jul 06, 2022 - 11:15 am

Odyssey Health, Inc. (ODYY) Optimistic About Drug/Tech IP as Industry Studies Big Pharma M&A Outlook

Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cashAmong promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”)…

Continue Reading

Friday Jul 01, 2022 - 9:00 am

Odyssey Health, Inc. (ODYY) Reports Positive Findings on Phase 1 Clinical Trials of PRV-002 for Concussions

No adverse reactions were reported in any of the healthy subjects enrolled in the Cohort II Phase 1 clinical trial of PRV-002 Company in talks with military training sites for Phase 2 and 3 clinical trials on concussed patientsThe CDC estimates that approximately 1.6 to 3.8 million sports and recreation-related concussions occur annually, for which there is no FDA-approved treatmentThe global concussion market size was valued…

Continue Reading

Wednesday Jun 29, 2022 - 10:30 am

Odyssey Health, Inc. (ODYY) Taps Military Advisors to Address Target Market for PRV-002 Concussion Drug

Odyssey Health is a medical company focused on developing medical products for conditions with unmet needs, one of which is concussionCurrently, concussions do not have an FDA-approved treatmentSoldiers form a significant population of people who frequently experience multiple concussions throughout their careerConcussion has only recently received greater attention as different parties seek to understand the condition and possible treatmentsOdyssey is at the forefront of this…

Continue Reading

Tuesday Jun 28, 2022 - 11:15 am

Aditxt Inc. (NASDAQ: ADTX) Authorizes New Channel Partner to Offer AditxtScore(TM) Amid Rising COVID-19 Cases and Possible Fall/Winter Waves

Aditxt, Inc. is a is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. The Company’s product AditxtScore(TM) is a proprietary immune mapping technology designed to provide a personalized profile of the immune system; AditxtScore(TM) for COVID-19 is the Aditxt’s first commercial productAditxt recently announced it had authorized a new channel partner – Premier Medical Laboratory Services (“PMLS”),…

Continue Reading

Monday Jun 27, 2022 - 2:15 pm

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study

Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substanceKernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeuticsTechnology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE American: CYBN) focus on and commitment to progressing psychedelics to therapeutics. The…

Continue Reading

Monday Jun 27, 2022 - 1:30 pm

Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease

In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer's Disease (“AD”).  SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies.  Columbia University Irving Medical Center (“CUIMC”), an “internationally recognized leader” in research and therapeutic development, partnered…

Continue Reading

Monday Jun 27, 2022 - 9:45 am

Odyssey Health, Inc. (ODYY) Targeting Achievement of Important Milestones, as It Progresses Clinical Trials of Novel Concussion Drug

Odyssey Health is focused on developing life-saving medical products and pharmaceutical assets that offer a technological and clinical advantageThe company is developing the CardioMap Heart Monitoring and Screening Device and the Save-a-Life choking rescue device Its drug-device combination is intended to get PRV-002, Odyssey’s novel treatment for concussion, to the brain rapidly after concussionIn an interview with RedChip Companies CEO Dave Gentry, Odyssey CEO Michael Redmond…

Continue Reading

Friday Jun 24, 2022 - 12:00 pm

Hope of Herd Immunity Dwindles Alongside Federal COVID-19 Budget and Supplies; Aditxt Inc. (NASDAQ: ADTX) and AditxtScore(TM) Could Create Map to COVID-19 Immune Responses

Two years after a vaccine was made available for COVID-19, fewer than 70% of Americans have been vaccinatedThe AditxtScore(TM) can provide the necessary answers to individualized immune response questions and direct on the best course of treatment for the individual – not the herdNo additional funding for COVID-19 relief has been approved by Congress, requiring the Biden Administration to reallocate funds to prepare for the…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).